-
AbbVie Inc. et al v. The Kennedy Trust Rheumatology Research DC CAFC
- 1:13-cv-01358
- S.D.N.Y.
- Judge: Paul A. Crotty
- Filed: 02/28/2013
- Closed: 07/09/2014
- Latest Docket Entry: 05/15/2015
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
0
Accused
Products
2
Patents-in-Suit
497
Days in
Litigation
-
AbbVie Inc. et al v. The Kennedy Trust Rheumatology Research DC CAFC
- 1:13-cv-01358
- S.D.N.Y.
- Judge: Paul A. Crotty
- Filed: 02/28/2013
- Closed: 07/09/2014
- Latest Docket Entry: 05/15/2015
- PACER
- Docket updated daily
Cause of Action
Declaratory Judgment
Patent Invalidity
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of treating an individual suffering from rheumatoid arthritis who, despite prior treatment with methotrexate, still has active disease, defined as the presence of six or more swollen joints plus at least three of the following four secondary
view more
|
Invalid (101 and 103)
Entry 64 Entry 63 |
2 |
The method of claim 1, wherein the antibody is administered subcutaneously or by intravenous infusion and is a chimeric, human, or humanized monoclonal antibody.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
6 |
The method of claim 2, wherein the antibody is administered subcutaneously and is a human or humanized monoclonal antibody.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
7 |
The method of claim 1, wherein the antibody is administered adjunctively.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
8 |
The method of claim 2, wherein the antibody is administered adjunctively.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
12 |
The method of claim 6, wherein the antibody is administered adjunctively.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
13 |
The method of claim 1, wherein the antibody is administered concomitantly.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
14 |
The method of claim 2, wherein the antibody is administered concomitantly.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
18 |
The method of claim 6, wherein the antibody is administered concomitantly.
|
Invalid (101 and 103)
Entry 64 Entry 63 |
19 |
The method of any of claims 1-18, wherein the method further results in the individual's rheumatoid arthritis going into remission or near remission.
|
Invalid (101 and 103)
Entry 64 Entry 63 |